Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhGH plus low-dose oral estrogen in prepubertal Turner syndrome
ChiCTR2600124301Phase 4Not yet recruiting
- Sponsor
- Chengdu Women's and Children's Central Hospital
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin and DehydraTECH-estrogen in Turner syndrome (TS) (2 arms), sponsored by Chengdu Women's and Children's Central Hospital. Primary endpoints: Height, Annual growth rate and 3 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
somatropinDehydraTECH-estrogen
03
Conditions
Turner syndrome (TS)
Beyond the preview
Go deeper on ChiCTR2600124301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124301.